API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ISP-001 (Iduronicrin Genleukocel-T) is the first product candidate developed using the company’s proprietary technique which is under phase 1 clinical development for the treatment of mucopolysaccharidosis type I (MPS I).
Lead Product(s): Iduronicrin Genleukocel-T
Therapeutic Area: Genetic Disease Product Name: ISP-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
This funding will support a Phase I study to evaluate the safety and tolerability of ISP-001 (for delivery of alpha-L-iduronidase, or IDUA) in MPS I a rare, childhood genetic disease.
Lead Product(s): Iduronicrin Genleukocel-T
Therapeutic Area: Genetic Disease Product Name: ISP-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 27, 2023
Details:
ISP-001 (iduronicrin genleukocel-T) represents the first product candidate developed using the company’s proprietary technique for the treatment of mucopolysaccharidosis type I (MPS I).
Lead Product(s): Iduronicrin Genleukocel-T
Therapeutic Area: Genetic Disease Product Name: ISP-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022